Biocon share price jumps over 4% after US FDA clears Malaysian insulin facility: Know More Here
Biocon’s share price rose 4.5% on Monday after the US Food and Drug Administration (US FDA) approved Biocon Biologics’ insulin facility in Malaysia. This development resolves a substantial regulatory impediment for the corporation. The Malaysian unit was recognized as a “Voluntary Action Indicated” (VAI) by the US drug regulator, allowing the company to file items…